

Early intravitreal bevacizumab for non-<sup>ischaemic</sup> cen

Acta Ophthalmologica

87, 77-81

DOI: [10.1111/j.1755-3768.2008.01313.x](https://doi.org/10.1111/j.1755-3768.2008.01313.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS. <i>Retina</i> , 2009, 29, 875-912.	1.0	215
2	Recent advances in drug delivery systems for treating ocular complications of systemic diseases. <i>Current Opinion in Ophthalmology</i> , 2009, 20, 511-519.	1.3	45
4	Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion. , 2010, , CD007325.		24
5	Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. <i>Eye</i> , 2010, 24, 810-815.	1.1	35
6	Intravitreal Bevacizumab Treatment of Macular Edema in Central Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2010, 51, 707.	0.0	7
7	Monoclonal Antibodies in Rare Acquired Thrombotic Disorders: The Paradigms of Paroxysmal Nocturnal Hemoglobinuria, Thrombotic Thrombocytopenic Purpura and Central Retinal Vein Occlusion. <i>Current Vascular Pharmacology</i> , 2010, 8, 51-58.	0.8	1
8	Results of bevacizumab as the primary treatment for retinal vein occlusions. <i>British Journal of Ophthalmology</i> , 2010, 94, 1052-1056.	2.1	68
9	Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion – A Matched-Pairs Analysis. <i>Ophthalmologica</i> , 2010, 224, 126-132.	1.0	15
11	Intravitreal triamcinolone after intravitreal bevacizumab for retinal vein occlusions. <i>Acta Ophthalmologica</i> , 2010, 88, e24-5.	0.6	6
12	Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®). <i>Acta Ophthalmologica</i> , 2010, 88, 836-841.	0.6	13
13	Intravitreal Bevacizumab for Macular Edema Due to Central Retinal Vein Occlusion: Perfused vs. Ischemic and Early vs. Late Treatment. <i>Current Eye Research</i> , 2011, 36, 1164-1170.	0.7	15
14	The Short-Term Efficacy of Intravitreal Ranibizumab for Macular Edema in Central Retinal Vein Occlusion. <i>Journal of Korean Ophthalmological Society</i> , 2011, 52, 1048.	0.0	3
15	Intravitreal Bevacizumab in Central Retinal Vein Occlusion: 18-month Results of a Prospective Clinical Trial. <i>European Journal of Ophthalmology</i> , 2011, 21, 789-795.	0.7	21
16	A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS. <i>Retina</i> , 2011, 31, 1449-1469.	1.0	131
17	Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: A pilot study. <i>Eye</i> , 2011, 25, 239-244.	1.1	14
18	Intravitreal Bevacizumab for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion: Eighteen-Month Results of a Prospective Trial. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2011, 27, 615-621.	0.6	28
19	Retinal Vein Occlusions. <i>Asia-Pacific Journal of Ophthalmology</i> , 2012, 1, 355-363.	1.3	1
20	Visual Acuity Outcome and Predictive Factors after Bevacizumab for Central Retinal Vein Occlusion. <i>European Journal of Ophthalmology</i> , 2012, 22, 1013-1018.	0.7	30

#	ARTICLE	IF	CITATIONS
21	Potential Anti-Vascular Endothelial Growth Factor Therapies for Central Retinal Vein Occlusion. <i>Drugs</i> , 2012, 72, 2063-2071.	4.9	4
22	Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes. <i>Acta Ophthalmologica</i> , 2012, 90, 357-361.	0.6	15
23	Combination therapy in diabetic macular oedema and retinal vein occlusion – past and present. <i>Acta Ophthalmologica</i> , 2012, 90, 580-589.	0.6	25
24	A clinical study to evaluate the efficacy of intravitreal Anti-VEGF therapy in treating macular edema due to retinal venous occlusions. <i>Medical Journal Armed Forces India</i> , 2013, 69, 260-267.	0.3	3
25	Intravitreal Triamcinolone Acetonide Compared With Bevacizumab for the Treatment of Patients With Macular Edema Secondary to Central Retinal Vein Occlusion. <i>Postgraduate Medicine</i> , 2013, 125, 51-58.	0.9	16
26	Meta-Analysis of the Effect of Intravitreal Bevacizumab Versus Intravitreal Triamcinolone Acetonide in Central Retinal Vein Occlusion. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 826-831.	0.6	5
27	Comparison of the effects of intravitreal bevacizumab and triamcinolone acetonide in the treatment of macular edema secondary to central retinal vein occlusion. <i>Indian Journal of Ophthalmology</i> , 2014, 62, 279.	0.5	8
28	Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion. <i>Documenta Ophthalmologica</i> , 2014, 129, 27-38.	1.0	9
29	Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up. <i>Seminars in Ophthalmology</i> , 2015, 31, 1-6.	0.8	6
30	Intravitreal anti-VEGF Treatment in Central Retinal Vein Occlusion (CRVO): a Meta-Analysis of One Year Results. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2017, 234, 546-550.	0.3	6
31	The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2020, 10, 13248.	1.6	42
32	Intravitreal injection of bevacizumab alone or with triamcinolone acetonide for treatment of macular edema caused by central retinal vein occlusion. <i>International Journal of Ophthalmology</i> , 2011, 4, 89-94.	0.5	11